Liver Toxicity After Treatment With Gefitinib and Anastrozole: Drug-Drug Interactions Through Cytochrome p450?
Paolo Carlini(National Cancer Institute), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Alessandra Felici, Alessandra Fabi(Agostino Gemelli University Polyclinic), Enzo Maria Ruggeri, Francesco Cognetti(Apple (Israel)), Carmen Nuzzo, Paola Papaldo(Cancer Institute (WIA)), Mariangela Ciccarese, Michèle Milella(National Cancer Institute)
Cited by 28
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
PTEN: Multiple Functions in Human Malignant Tumors
|Frontiers in Oncology|2015|460